Systematic review / meta-analysis / 2010
Higher circulating IGF1 concentrations were linked to an increased risk of breast cancer, particularly estrogen-receptor-positive tumors.
Researchers pooled individual data from 17 prospective studies across 12 countries to examine circulating IGF1 and IGFBP3 levels in relation to breast cancer risk (4,790 cases and 9,428 matched controls). The odds ratio for breast cancer comparing the highest to the lowest fifth of IGF1 concentration was 1.28 (95% CI 1.14-1.44; p<0.0001). This association was not altered by adjusting for IGFBP3 and did not vary significantly by menopausal status. However, risk differed by tumor type: the OR was 1.38 (95% CI 1.14-1.68) for estrogen-receptor-positive tumors versus 0.80 (95% CI 0.57-1.13) for estrogen-receptor-negative tumors (p for heterogeneity = 0.007). In controls, IGF1 concentrations were higher in moderately overweight women and moderate alcohol consumers.
Shows an association, not proof of cause and effect.
- Study type
- Pooled individual data analysis of 17 prospective studies
- Who was studied
- 4,790 breast cancer cases and 9,428 matched controls from 17 prospective studies across 12 countries
- What was measured
- Odds ratios of breast cancer associated with circulating IGF1 and IGFBP3 concentrations
THE PAPER
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies.
Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW. Lancet Oncol, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.